These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 38844855

  • 1. Safety and adherence of bictegravir/emtricitabine/tenofovir alafenamide for HIV post-exposure prophylaxis among adults in Guiyang China: a prospective cohort study.
    Gan L, Xie X, Fu Y, Yang X, Ma S, Kong L, Song C, Song Y, Ren T, Long H.
    BMC Infect Dis; 2024 Jun 06; 24(1):565. PubMed ID: 38844855
    [Abstract] [Full Text] [Related]

  • 2. Rapid Initiation of Antiretroviral Therapy With Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide Versus Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate in HIV-Positive Men Who Have Sex With Men in China: Week 48 Results of the Multicenter, Randomized Clinical Trial.
    Wang R, Sun L, Wang X, Zhai Y, Wang L, Ma P, Wu C, Zhou Y, Chen R, Wang R, Zhang F, Hua W, Li A, Xia W, Gao Y, Li R, Lv S, Shao Y, Cao Y, Zhang T, Wu H, Cai C, Dai L.
    Clin Infect Dis; 2024 Jul 19; 79(1):169-176. PubMed ID: 38236137
    [Abstract] [Full Text] [Related]

  • 3. Rapid initiation of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy in HIV infection. A prospective study.
    Ugarte A, De La Mora L, De Lazzari E, Chivite I, Fernández E, Inciarte A, Laguno M, Ambrosioni J, Solbes E, Berrocal L, González-Cordón A, Martínez-Rebollar M, Foncillas A, Calvo J, Blanco JL, Martínez E, Mallolas J, Torres B.
    J Antimicrob Chemother; 2024 Sep 03; 79(9):2343-2353. PubMed ID: 39045754
    [Abstract] [Full Text] [Related]

  • 4. Health care resource utilization and costs for treatment-experienced people with HIV switching or restarting antiretroviral regimens since 2018.
    Colson A, Chastek B, Gruber J, Majethia S, Zachry W, Mezzio D, Rock M, Anderson A, Cohen JP.
    J Manag Care Spec Pharm; 2024 Aug 03; 30(8):817-824. PubMed ID: 39088337
    [Abstract] [Full Text] [Related]

  • 5. Safety and Tolerability of Once Daily Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Exposure.
    Mayer KH, Gelman M, Holmes J, Kraft J, Melbourne K, Mimiaga MJ.
    J Acquir Immune Defic Syndr; 2022 May 01; 90(1):27-32. PubMed ID: 34991141
    [Abstract] [Full Text] [Related]

  • 6. [Translated article] Real-world persistence with dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir-alafenamide among persons with HIV.
    Martín-Zaragoza L, Sánchez-Rubio-Ferrández J, Onteniente-González A, Gómez-Bermejo M, Rodríguez-Álvarez SJ, Monereo-Alonso A, Molina-García T.
    Farm Hosp; 2024 May 01; 48(4):T171-T175. PubMed ID: 38806363
    [Abstract] [Full Text] [Related]

  • 7. An open-label evaluation of safety and tolerability of coformulated bictegravir/emtricitabine/tenofovir alafenamide for post-exposure prophylaxis following potential exposure to human immunodeficiency virus-1.
    Liu A, Xin R, Zhang H, Dai L, Wu RE, Wang X, Li A, Hua W, Li J, Shao Y, Gao Y, Wang Z, Ye J, Bu Dou Re Xi Ti GA, Li Z, Sun L.
    Chin Med J (Engl); 2022 Nov 20; 135(22):2725-2729. PubMed ID: 36719359
    [Abstract] [Full Text] [Related]

  • 8. Effectiveness, safety and discontinuation rates of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with HIV using real-world data: a systematic review and meta-analysis.
    Chivite I, Berrocal L, de Lazzari E, Navadeh S, Lluis-Ganella C, Inciarte A, de la Mora L, González-Cordón A, Martínez-Rebollar M, Laguno M, Torres B, Blanco JL, Martínez E, Mallolas J, Ambrosioni J.
    J Antimicrob Chemother; 2024 Aug 01; 79(8):1775-1783. PubMed ID: 38758191
    [Abstract] [Full Text] [Related]

  • 9. Comparing the efficacy and safety of a first-line regimen with emtricitabine/tenofovir alafenamide fumarate plus either bictegravir or dolutegravir: Results from clinical practice.
    Ciccullo A, Baldin G, Borghi V, Oreni L, Lagi F, Fusco P, Giacomelli A, Torti C, Sterrantino G, Mussini C, Antinori S, Di Giambenedetto S.
    Int J Antimicrob Agents; 2024 Jan 01; 63(1):107040. PubMed ID: 37981074
    [Abstract] [Full Text] [Related]

  • 10. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance.
    Acosta RK, Willkom M, Andreatta K, Liu H, Martin R, Parvangada A, Martin H, Collins S, White KL.
    J Acquir Immune Defic Syndr; 2020 Nov 01; 85(3):363-371. PubMed ID: 32701823
    [Abstract] [Full Text] [Related]

  • 11. Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy.
    Orkin C, Antinori A, Rockstroh JK, Moreno-Guillén S, Martorell CT, Molina JM, Lazzarin A, Maggiolo F, Yazdanpanah Y, Andreatta K, Huang H, Hindman JT, Martin H, Pozniak A.
    AIDS; 2024 Jun 01; 38(7):983-991. PubMed ID: 38349226
    [Abstract] [Full Text] [Related]

  • 12. Short-term neuropsychiatric tolerability of bictegravir combined with emtricitabine/tenofovir alafenamide in clinical practice.
    Hoffmann C, Schewe K, Fenske S, Buhk T, Sabranski M, Adam A, Hansen S, Stellbrink HJ.
    Antivir Ther; 2020 Jun 01; 25(2):83-90. PubMed ID: 32235038
    [Abstract] [Full Text] [Related]

  • 13. Bictegravir/emtricitabine/tenofovir alafenamide as first-line treatment in naïve HIV patients in a rapid-initiation model of care: BIC-NOW clinical trial.
    Hidalgo-Tenorio C, Sequera S, Vivancos MJ, Vinuesa D, Collado A, Santos IL, Sorni P, Cabello-Clotet N, Montero M, Font CR, Terron A, Galindo MJ, Martinez O, Ryan P, Omar-Mohamed M, Albendín-Iglesias H, Javier R, Ruz MÁL, Romero A, Garcia-Vallecillos C.
    Int J Antimicrob Agents; 2024 Jun 01; 63(6):107164. PubMed ID: 38574873
    [Abstract] [Full Text] [Related]

  • 14. Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial.
    Mills AM, Rizzardini G, Ramgopal MN, Osiyemi OO, Bogner JR, Hagins DP, Paredes R, Reynes J, Rockstroh JK, Carr A, Su FH, Klopfer SO, Eves K, Plank RM, Correll T, Fox MC.
    Lancet HIV; 2024 Jun 01; 11(6):e357-e368. PubMed ID: 38734016
    [Abstract] [Full Text] [Related]

  • 15. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
    Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard PM, Brar I, Daar ES, Wohl D, Rockstroh J, Wei X, Custodio J, White K, Martin H, Cheng A, Quirk E.
    Lancet; 2017 Nov 04; 390(10107):2063-2072. PubMed ID: 28867497
    [Abstract] [Full Text] [Related]

  • 16. Integrase strand transfer inhibitor resistance mediated by R263K plus E157Q in a patient with HIV infection treated with bictegravir/tenofovir alafenamide/emtricitabine: case report and review of the literature.
    Buzon-Martin L, Navarro-San Francisco C, Fernandez-Regueras M, Sanchez-Gomez L.
    J Antimicrob Chemother; 2024 May 02; 79(5):1153-1156. PubMed ID: 38558010
    [Abstract] [Full Text] [Related]

  • 17. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
    Molina JM, Ward D, Brar I, Mills A, Stellbrink HJ, López-Cortés L, Ruane P, Podzamczer D, Brinson C, Custodio J, Liu H, Andreatta K, Martin H, Cheng A, Quirk E.
    Lancet HIV; 2018 Jul 02; 5(7):e357-e365. PubMed ID: 29925489
    [Abstract] [Full Text] [Related]

  • 18. Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort.
    d'Arminio Monforte A, Tavelli A, Di Biagio A, Sarmati L, Marchetti GC, Bai F, Cingolani A, Quiros Roldan E, Mussini C, Lichtner M, Vergori A, Piconi S, Orofino G, Fusco FM, Bandera A, Nozza S, Castagna A, Antinori A, ICONA Foundation Study Group.
    J Antimicrob Chemother; 2024 Jun 03; 79(6):1279-1288. PubMed ID: 38581349
    [Abstract] [Full Text] [Related]

  • 19. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
    Sax PE, Pozniak A, Montes ML, Koenig E, DeJesus E, Stellbrink HJ, Antinori A, Workowski K, Slim J, Reynes J, Garner W, Custodio J, White K, SenGupta D, Cheng A, Quirk E.
    Lancet; 2017 Nov 04; 390(10107):2073-2082. PubMed ID: 28867499
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-arm study.
    Rodriguez CA, Natukunda E, Strehlau R, Venter EL, Rungmaitree S, Cunningham CK, Lalloo U, Kosalaraksa P, HellstrÖm E, Liberty A, McGrath EJ, Kaur M, Leisegang R, Hindman JT, Vieira VA, Kersey K, Cotton MF, Rakhmanina N, Gaur AH.
    Lancet HIV; 2024 May 04; 11(5):e300-e308. PubMed ID: 38621393
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.